136 related articles for article (PubMed ID: 38236934)
1. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
Westerberg M; Irenaeus S; Garmo H; Stattin P; Gedeborg R
PLoS One; 2024; 19(1):e0296804. PubMed ID: 38236934
[TBL] [Abstract][Full Text] [Related]
2. An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts.
Gedeborg R; Sund M; Lambe M; Plym A; Fredriksson I; Syrjä J; Holmberg L; Robinson D; Stattin P; Garmo H
Epidemiology; 2021 Jul; 32(4):607-615. PubMed ID: 33935137
[TBL] [Abstract][Full Text] [Related]
3. Improved prediction of long-term, other cause mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
[TBL] [Abstract][Full Text] [Related]
4. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
5. How to model temporal changes in comorbidity for cancer patients using prospective cohort data.
Lindhagen L; Van Hemelrijck M; Robinson D; Stattin P; Garmo H
BMC Med Inform Decis Mak; 2015 Nov; 15():96. PubMed ID: 26582418
[TBL] [Abstract][Full Text] [Related]
6. Prediction of mortality after radical prostatectomy by Charlson comorbidity index.
Guzzo TJ; Dluzniewski P; Orosco R; Platz EA; Partin AW; Han M
Urology; 2010 Sep; 76(3):553-7. PubMed ID: 20627284
[TBL] [Abstract][Full Text] [Related]
7. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
8. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the performance of the Charlson Comorbidity Index (CCI) in fracture risk prediction and developing a new Charlson Fracture Index (CFI): a register-based cohort study.
Clausen A; Möller S; Skjødt MK; Bech BH; Rubin KH
Osteoporos Int; 2022 Mar; 33(3):549-561. PubMed ID: 34993562
[TBL] [Abstract][Full Text] [Related]
10. Consideration of comorbidity in risk stratification prior to prostate biopsy.
Liss MA; Billimek J; Osann K; Cho J; Moskowitz R; Kaplan A; Szabo RJ; Kaplan SH; Greenfield S; Dash A
Cancer; 2013 Jul; 119(13):2413-8. PubMed ID: 23619920
[TBL] [Abstract][Full Text] [Related]
11. Causes of death in men with localized prostate cancer: a nationwide, population-based study.
Van Hemelrijck M; Folkvaljon Y; Adolfsson J; Akre O; Holmberg L; Garmo H; Stattin P
BJU Int; 2016 Mar; 117(3):507-14. PubMed ID: 25604807
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
14. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.
Pettersson A; Robinson D; Garmo H; Holmberg L; Stattin P
Ann Oncol; 2018 Feb; 29(2):377-385. PubMed ID: 29161337
[TBL] [Abstract][Full Text] [Related]
15. Optimized diagnosis-based comorbidity measures for all-cause mortality prediction in a national population-based ICU population.
Aronsson Dannewitz A; Svennblad B; Michaëlsson K; Lipcsey M; Gedeborg R
Crit Care; 2022 Oct; 26(1):306. PubMed ID: 36203163
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of the Modified Charlson Comorbidity Index in Incident Peritoneal Dialysis Patients: A National Population-Based Approach.
Cho H; Kim MH; Kim HJ; Park JY; Ryu DR; Lee H; Lee JP; Lim CS; Kim KH; Oh KH; Joo KW; Kim YS; Kim DK
Perit Dial Int; 2017 1-2; 37(1):94-102. PubMed ID: 27605681
[TBL] [Abstract][Full Text] [Related]
17. Comorbidity and competing risks for mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
[TBL] [Abstract][Full Text] [Related]
18. Patient comorbidity is associated with conservative treatment of localized prostate cancer.
Jespersen CG; Nørgaard M; Jacobsen JB; Borre M
Scand J Urol; 2015; 49(5):366-70. PubMed ID: 25903072
[TBL] [Abstract][Full Text] [Related]
19. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Yonsei Med J; 2014 Mar; 55(2):316-23. PubMed ID: 24532498
[TBL] [Abstract][Full Text] [Related]
20. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus.
Jönsen A; Clarke AE; Joseph L; Belisle P; Bernatsky S; Nived O; Bengtsson AA; Sturfelt G; Pineau CA
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1233-7. PubMed ID: 21618451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
